Liprimar 30 tablets 10mg & 20mg & 40mg & 80mg Atorvastatin Atorvastatinum Липримар

Liprimar Indications

Prevention of cardiovascular disease

Adult patients without clinically significant coronary heart disease but with multiple risk factors for coronary heart disease, such as age, smoking, hypertension, low HDL levels or the presence of early coronary heart disease in the family history, Liprymar® indicated for:

- Reduce the risk of myocardial infarction;

- Reducing the risk of stroke;

- Reducing the risk of revascularization procedures and angina.

For patients with type II diabetes and no clinically significant coronary heart disease but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking or hypertension, the drug is indicated for Liprymar®:

     - Reduce the risk of myocardial infarction;

     - Reducing the risk of stroke.

For patients with clinical coronary heart disease Liprymar® indicated for:

     - Reducing the risk of non-lethal myocardial infarction;

     - Reduce the risk of lethal and non-lethal stroke;

     - Reducing the risk of revascularization procedures;

     - Reducing the risk of hospitalization due to congestive heart failure;

     - Reducing the risk of strokes.

Contraindications

- Active liver disease, which may include a persistent increase in liver enzymes of unknown etiology.

- Hypersensitivity to any component of this medication.

Dosage & Administration

Hyperlipidemia (heterozygous familial and non-family) and mixed dyslipidemia (type IIa and IIb Fredrickson classification)

The recommended starting dose is 10 Liprymar or 20 mg 1 time a day. For patients requiring a significant reduction in LDL-C (over 45%), therapy may be initiated dosing of 40 mg 1 time a day. Dose range Liprymar drug is in the range of 10 to 80 mg 1 time a day. The drug can make a one-time dose at any hour and regardless of the meal. Initial and maintenance doses of drug Liprymar should be individualized depending on the purpose of treatment and response. After the treatment and / or upon titration of the dose should examine Liprymar lipid levels over a period of 2 to 4 weeks and dosage adjusted accordingly.

Heterozygous familial hypercholesterolemia in pediatric patients (aged 10-17 years)

The recommended starting dose is 10 mg Liprymar / day; The maximum recommended dose - 20 mg / day (doses exceeding 20 mg in this group of patients not studied). The dose should be individualized according to the recommended goal of therapy. Dose adjustment should be made at intervals of 4 weeks or more.

Homozygous familial hypercholesterolemia

Dose Liprymar for patients with homozygous familial hypercholesterolemia is 10 to 80 mg per day. Liprymar can be used as an adjunct to other lipid-lowering treatments (eg LDL apheresis) or if lipid-lowering treatments available.